In the publication of its 2015 Annual Report to shareholders, GSK plc today announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017
The Company today announces that Sir Deryck Maughan, Dr Stephanie Burns, Dr Daniel Podolsky and Hans Wijers will not stand for re-election to the Board at GSK’s Annual General Meeting on 5 May 2016.
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma
GSK today announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study.
Collaboration includes discovery programme for CAR-T cell-based oncology therapies
$1 million GSK IMPACT Grant awarded to build healthy futures for young people aging out of foster care in the Triangle
$1 million GSK IMPACT Grant awarded to build healthy futures for young people aging out of foster care in the Triangle. 7 nonprofit organizations help 500 young people transition to healthy adulthood
Free summer science program will teach thousands of kids how electricity powers our daily lives
GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels
GSK today presented results at the American Academy of Allergy, Asthma & Immunology annual meeting from a post-hoc study which showed that severe asthma patients with a baseline blood eosinophil count of 150 cells/L or above who received Nucala® (100mg fixed dose subcutaneous injection of mepolizumab) or an investigational dose of mepolizumab had a significant improvement in their exacerbation rates compared to those receiving placebo.
NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma
GSK today announced publication of results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine.
GSK presents new data on the long-term efficacy & safety of Nucala® for the treatment of severe asthma with an eosinophilic phenotype
GSK today presented new safety and efficacy data for Nucala® (mepolizumab) from the open-label COSMOS (MEA115661) study at the American Academy of Allergy, Asthma & Immunology annual meeting.
Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America